# Immunogenicity of an Inactivated COVID-19 Vaccine

> **NCT05198336** · PHASE4 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 395 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05198336
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-08
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-12-30
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198336, "Immunogenicity of an Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05198336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*